All Access

Health Tech Deals

Health Tech Deals Alerts

Alert

Standard

Health Tech Deals Thought Bubble

Thought Bubble

mustard

BFD Expert Voices - Health Tech Deals

BFD Expert Voices

Women's health unicorn Maven Clinic sees growth opportunities in the rise of wearables and Big Tech's push into health care, CEO Kate Ryder said Monday night.

Why it matters: The New York-based company is on digital health's IPO shortlist, but at the JPMorgan Healthcare Conference, Ryder declined to comment on timing. 

Ryder spoke with Axios at the event in San Francisco. This interview has been lightly edited for length and clarity.

"We made some (acquisition) offers last year. But, man, a lot of boards just are keeping the valuations high. 

We're always looking and ... digital health rollups are very ripe for the coming. So maybe there'll be news."

How does OpenAI's entry into health care impact Maven?

"If we look at somebody starting a fertility journey ... maybe they've been feeding a lot of their early diagnostics into OpenAI, and they want to know that agent is going to then talk to our agent to get them ready for IVF, for whatever pathway they're going to go down. 

Maybe it's natural conception, but we're going to be the specialist there, because we have a proprietary data set in women's health that they don't, quite frankly."

How do you ensure patients can trust Maven with sensitive data?

"We have always used all patient data to just make our care model better, and we've never sold data. That's never how we've monetized our business model. 

You actually need to train AI to be uncertain, and you need to train AI to be a lot more humble. 

Women's health is an area of health care where there's just not as much data and research as other categories. So you can't be overconfident if you're trying to define a care pathway for someone with PCOS, who has a lot more of a complex medical history."

Maven's done work with smart ring maker Oura. What's next?

"We're in a really interesting study with them right now, where we're looking at Maven patients using Oura and Maven patients not using Oura, and looking at outcomes.

It's now easier to get medical history from health information exchanges, EMRs like that. 

Data interoperability is here, and it's only getting better ... But what you're still lacking when you want to have a real complete picture of a patient is that real-time data that Oura is giving you, on body temperature, on sleep."

Maven Clinic CEO talks M&A, Oura and Open AI

Already on IPO shortlists, Maven has its eye on acquisitions.

Erin Brodwin from Axios Pro on stage with Maven Clinic CEO Kate Ryder

Axios Pro's Erin Brodwin with Maven Clinic CEO Kate Ryder. Credit: Chris Constantine on behalf of Axios

Women&#x27;s health unicorn <a class="gtmContentClick" data-vars-link-text="Maven Clinic" data-vars-click-url="https://www.axios.com/pro/health-tech-deals/2024/10/08/maven-clinic-125-million-series-f-women-family-health" data-vars-content-id="7ba8e5d9-11d3-406c-ad60-d89fc7808e95" data-vars-headline="Maven Clinic CEO talks M&amp;A, Oura and Open AI" data-vars-event-category="story" data-vars-sub-category="story" data-vars-item="in_content_link" href="https://www.axios.com/pro/health-tech-deals/2024/10/08/maven-clinic-125-million-series-f-women-family-health" target="_self">Maven Clinic</a> sees growth opportunities in the rise of wearables and Big Tech&#x27;s push into health care, CEO Kate Ryder said Monday night.Why it matters: The New York-based company is on digital health&#x27;s IPO <a class="gtmContentClick" data-vars-link-text="shortlist" data-vars-click-url="https://www.axios.com/pro/health-tech-deals/2025/05/01/digital-health-companies-test-ipo" data-vars-content-id="7ba8e5d9-11d3-406c-ad60-d89fc7808e95" data-vars-headline="Maven Clinic CEO talks M&amp;A, Oura and Open AI" data-vars-event-category="story" data-vars-sub-category="story" data-vars-item="in_content_link" href="https://www.axios.com/pro/health-tech-deals/2025/05/01/digital-health-companies-test-ipo" target="_self">shortlist</a>, but at the JPMorgan Healthcare Conference, Ryder declined to comment on timing.

topics

politics-policy

epstein-files

donald-trump

2026-midterm-elections

immigration

behind-the-curtain

race-and-equity

technology

privacy-tech-regulation

automation-and-ai

tiktok-news

big-tech

social-media

cybersecurity

economy

social-security

inflation

tariffs

federal-reserve

jobs

transportation

business

stock-market-news

retail-news

crypto

media

elon-musk

dealmaking

health

rfk-jr

drug-prices

axios-explains-abortion

public-health

world

israel

axios-explains-ukraine

iran

russia

china

energy-climate

nuclear-energy

climate-energy-policy

climate-change

extreme-weather

alternative-energy

electric-vehicles

science

emerging-tech

biomedicine

newsletters

charlotte

boulder

detroit

kansas-city

columbus

austin

dallas

atlanta

washington-dc

nw-arkansas

chicago

indianapolis

nashville

richmond

colorado-springs

houston

san-francisco

seattle

boston

des-moines

salt-lake-city

philadelphia

denver

phoenix

new-orleans

miami

twin-cities

raleigh

san-antonio

portland

san-diego

tampa-bay

cleveland

huntsville

pittsburgh

axios-local

axios-pro

axios-live

the-axios-show

Maven Clinic CEO talks M&A, Oura and Open AI

What to read next